Page 136 - Haematologica March 2020

M. Hoeks et al.
the results were seen in the analysis of the unmatched samples. Therefore, in this case, propensity-score match- ing will probably not have led to significant selection bias. Finally, despite using a large control group, eligible for using ICT, and a propensity-score matched analysis corrected for many known and measured confounders, we cannot exclude residual confounding. Considering the size of the effect, it is unlikely that residual confounding would explain the difference found between chelated and non-chelated patients.
In summary, the results of this study suggest that ICT may improve OS and hematopoiesis in transfused LR- MDS patients.
Acknowledgments
The authors and members of the steering committee of the EUMDS registry would like to thank all local investigators and operational team members for their contribution to the registry, and W. Thomas Johnston for his contribution to the analyses.
Funding
The EUMDS Registry is supported by an educational grant from Novartis Pharmacy B.V. Oncology Europe, and Amgen Limited. This work is part of the MDS-RIGHT activities, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634789 - “Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time”.
References
1. Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841-4851.
2. Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013;2013:447-456.
3. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-761.
4. Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016; 388(10045):706-716.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
6. Porter JB, de Witte T, Cappellini MD, et al. New insights into transfusion-related iron toxicity: Implications for the oncologist. Crit Rev Oncol Hematol. 2016;99:261-271.
7. Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve sur- vival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res. 2010; 34(7):864-870.
8. Raptis A, Duh MS, Wang ST, et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clini- cal practices. Transfusion. 2010;50(1):190- 199.
9. Neukirchen J, Fox F, Kündgen A, et al. Improved survival in MDS patients receiv- ing iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk Res. 2012; 36(8):1067-1070.
10. Delforge M, Selleslag D, Beguin Y, et al. Adequate iron chelation therapy for at least six months improves survival in transfu- sion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014;38(5):557-563.
11. Messa E, Biale L, Castiglione A, et al. Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic ane- mia with transfusion requirement and iron overload: a FISM Italian multicenter retro- spective study. Leuk Lymphoma. 2017;58(11):2752-2754.
12. Angelucci E, Santini V, Di Tucci AA, et al. Deferasirox for transfusion-dependent
patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur J Haematol. 2014;92(6):527-536.
13. Nolte F, Höchsmann B, Giagounidis A, et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the effica- cy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013;92(2):191-198.
14. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with trans- fusional iron overload. Br J Haematol. 1996;94(2):288-299.
15. List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion- dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30(17):2134- 2139.
16. Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;9(9):1364-1371.
17. Breccia M, Voso MT, Aloe Spiriti MA, et al. An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mecha- nisms. Ann Hematol. 2015;94(5):771-777.
18. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol. 2000;72(2):131-133.
19. Caliendo M, Kopeinig S. SOME PRACTI- CAL GUIDANCE FOR THE IMPLEMEN- TATION OF PROPENSITY SCORE MATCHING. Journal of Economic Surveys. 2008;22(1):31-72.
20. Rosenbaum PR, Rubin DB. Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score. The American Statistician. 1985;39(1):33-38.
21. Stürmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not sub- stantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437-447.
22. Schafer JL. Analysis of Incomplete
Multivariate Data: Taylor & Francis, 1997. 23. Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time- dependent covariates. Int J Methods
Psychiatr Res. 2002;11(2):68-74.
24. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-
425.
25. Zeidan AM, Hendrick F, Friedmann E, et al.
Deferasirox therapy is associated with reduced mortality risk in a medicare popu- lation with myelodysplastic syndromes. J Comp Eff Res. 2015;4(4):327-340.
26. Mainous AG, Tanner RJ, Hulihan MM, et al. The impact of chelation therapy on sur- vival in transfusional iron overload: a meta- analysis of myelodysplastic syndrome. Br J Haematol. 2014;167(5):720-723.
27. Remacha Á, Arrizabalaga B, Villegas A, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complica- tions. Ann Hematol. 2015;94(5):779-787.
28. Lyons RM, Marek BJ, Paley C, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. Leuk Res. 2017;56:88- 95.
29. Angelucci E, Li J, Greenberg PL, et al. Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-over- loaded patients with low- and intermedi- ate-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double blind Telesto study. Blood, annual meeting abstracts. 2018;132(S1):abstract 234.
30. Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179(1):83-97.
31. de Swart L, Reiniers C, Bagguley T, et al. Labile plasma iron levels predict survival in patients with lower-risk Myelodysplastic syndromes. Haematologica. 2018; 103(1):69-79.
32. Hoeks M, Bagguley T, Roelofs R, et al. Elevated labile plasma iron (LPI) levels in patients with lower-risk myelodysplastic syndromes (MDS) are associated with
650
haematologica | 2020; 105(3)